Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07811752) titled 'Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Chest Hospital
Condition:
Esophageal Squamous Cell Carcinoma
Intervention:
Drug: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: July 30, 2026
Target Sample Size: 28
Countries of Recruitment:
China
To know more, visit https://clinicalt...